GW Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 07 2020 - 1:13PM
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the
Group), the world leader in the science, development, and
commercialization of cannabinoid prescription medicines, today
announced that Justin Gover, GW’s Chief Executive Officer, will
present a business update at the 38th Annual J.P. Morgan Healthcare
Conference on Tuesday, January 14, 2020 at 11:00 am PT (2:00 pm ET)
at The Westin St. Francis in San Francisco. In addition, a Q&A
breakout session will immediately follow the presentation at 11:30
am PT (2:30 pm ET).
Live audio webcasts of the presentation and
breakout session will be available through GW’s corporate website
at www.gwpharm.com on the Investors section under Events &
Presentations. A replay will be available for each soon after the
live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. GW’s lead
product, EPIDIOLEX (cannabidiol) oral solution is commercialized in
the U.S. by its U.S. subsidiary Greenwich Biosciences for the
treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
or Dravet syndrome in patients two years of age or older. This
product has received approval in the European Union under the
tradename EPIDYOLEX. The Company expects to expand the indication
of EPIDIOLEX to include seizures associated with Tuberous Sclerosis
Complex (TSC), for which it has reported positive Phase 3 data, and
is carrying out a Phase 3 trial in Rett syndrome. GW commercialized
the world’s first plant-derived cannabinoid prescription drug,
Sativex® (nabiximols), which is approved for the treatment of
spasticity due to multiple sclerosis in numerous countries outside
the United States and for which the Company is now advancing a late
stage program in order to seek FDA approval. The Company has a deep
pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 trials for epilepsy, autism,
and schizophrenia. For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
|
|
|
|
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2023 to Jul 2024